Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Insider Transactions

Date Name Title Type Shares Traded Price Range
Jan 09, 2018
Director
Director Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 8,818 $11.34
Jan 09, 2018
Director
Director Other acquisition or disposition -- --
Jan 09, 2018
Director
Director Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 478,495 $4.65
Jan 09, 2018
Director
Director Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 500,000 --
Jan 09, 2018
Director
Director Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 650,000 --
Nov 30, 2017
Director, Chairman & CEO
Director, Chairman & CEO Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 16,545 $19.04
Nov 30, 2017
Director, Chairman & CEO
Director, Chairman & CEO Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 100,000 $3.15
Nov 30, 2017
Director, Chairman & CEO
Director, Chairman & CEO Other acquisition or disposition -- --
Nov 30, 2017
Director, Chairman & CEO
Director, Chairman & CEO Other acquisition or disposition -- --
Nov 30, 2017
Director, Chairman & CEO
Director, Chairman & CEO Other acquisition or disposition -- --
Nov 30, 2017
Director, Chairman & CEO
Director, Chairman & CEO Other acquisition or disposition -- --
Nov 30, 2017
Director, Chairman & CEO
Director, Chairman & CEO Bona fide gift 27,666 $19.04
Nov 30, 2017
Director, Chairman & CEO
Director, Chairman & CEO Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 100,000 --
Nov 30, 2017
Director, Chairman & CEO
Director, Chairman & CEO Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 27,666 $19.04
Jul 17, 2017
Director
Director Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 15,000 $6.90
Jul 17, 2017
Director
Director Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 442 $7.53
Jul 17, 2017
Director
Director Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 13,745 $7.53
Jul 17, 2017
Director
Director Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 15,000 --
Jul 17, 2017
Director
Director Other acquisition or disposition -- --
Jul 17, 2017
Director
Director Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 15,000 --
Jul 17, 2017
Director
Director Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 442 $7.53
Jul 17, 2017
Director
Director Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 15,000 $6.90
Jul 17, 2017
Director
Director Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 13,745 $7.53
Jun 27, 2017
Director
Director Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 625 $7.54
Jun 27, 2017
Director
Director Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 880 $7.54

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.

Back to top

Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Copyright Nasdaq. Minimum 15 minutes delayed.